- Home
- AKAN vs NDRA Comparison
AKAN vs NDRA Comparison
Compare AKAN & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKAN
- NDRA
- Stock Information
- Founded
- AKAN 2021
- NDRA 2007
- Country
- AKAN Canada
- NDRA United States
- Employees
- AKAN N/A
- NDRA N/A
- Industry
- AKAN Medicinal Chemicals and Botanical Products
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- AKAN Health Care
- NDRA Health Care
- Exchange
- AKAN Nasdaq
- NDRA Nasdaq
- Market Cap
- AKAN 2.9M
- NDRA 3.1M
- IPO Year
- AKAN 2022
- NDRA 2017
- Fundamental
- Price
- AKAN $3.29
- NDRA $4.16
- Analyst Decision
- AKAN
- NDRA Strong Buy
- Analyst Count
- AKAN 0
- NDRA 1
- Target Price
- AKAN N/A
- NDRA $46.00
- AVG Volume (30 Days)
- AKAN 160.1K
- NDRA 28.4K
- Earning Date
- AKAN 10-29-2025
- NDRA 08-14-2025
- Dividend Yield
- AKAN N/A
- NDRA N/A
- EPS Growth
- AKAN N/A
- NDRA N/A
- EPS
- AKAN N/A
- NDRA N/A
- Revenue
- AKAN $836,664.00
- NDRA N/A
- Revenue This Year
- AKAN N/A
- NDRA N/A
- Revenue Next Year
- AKAN N/A
- NDRA N/A
- P/E Ratio
- AKAN N/A
- NDRA N/A
- Revenue Growth
- AKAN 97.47
- NDRA N/A
- 52 Week Low
- AKAN $2.91
- NDRA $2.90
- 52 Week High
- AKAN $8.75
- NDRA $22.68
- Technical
- Relative Strength Index (RSI)
- AKAN 38.53
- NDRA 40.57
- Support Level
- AKAN $3.35
- NDRA $4.06
- Resistance Level
- AKAN $3.86
- NDRA $4.69
- Average True Range (ATR)
- AKAN 0.39
- NDRA 0.30
- MACD
- AKAN -0.08
- NDRA 0.03
- Stochastic Oscillator
- AKAN 11.29
- NDRA 22.54
About AKAN Akanda Corp.
Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company has three reportable segments: Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Distribution segment, which relates to the distribution of medical cannabis products, including cannabis oil and cannabis flower for medical use in the United Kingdom.
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.